CXCR5 and adenocarcinoma: CXCR5 expression was found to be lower in the adenocarcinoma group than in the other cancer groups by the Mann-Whitney test (P=0.043) (Figure 5B), CXCL13 was higher in the benefit group than in the no-benefit group (P=0.032) (Figure 5C), and a better PFS benefit was found in the high CD8 group than in the low CD8 group by the Kaplan-Meier survival curve (P=0.022) (Figure 5D).